Akebia Therapeutics, Inc. (NASDAQ:AKBA) has earned a consensus recommendation of “Buy” from the eleven analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $21.38.

Several equities research analysts recently commented on the company. BTIG Research assumed coverage on Akebia Therapeutics in a research report on Thursday. They set a “buy” rating and a $30.00 target price on the stock. ValuEngine upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. HC Wainwright reiterated a “buy” rating and issued a $24.00 price target on shares of Akebia Therapeutics in a report on Wednesday, August 9th. Finally, Royal Bank Of Canada initiated coverage on Akebia Therapeutics in a report on Thursday, September 14th. They issued a “sector perform” rating and a $17.00 price target on the stock.

In other news, SVP Michel Dahan sold 1,398 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $19.64, for a total value of $27,456.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold 7,586 shares of company stock worth $147,289 in the last 90 days. Corporate insiders own 7.95% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Creative Planning increased its position in Akebia Therapeutics by 2.9% in the second quarter. Creative Planning now owns 10,650 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 300 shares during the last quarter. Rhumbline Advisers increased its position in Akebia Therapeutics by 1.3% in the second quarter. Rhumbline Advisers now owns 41,510 shares of the biopharmaceutical company’s stock worth $596,000 after buying an additional 518 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Akebia Therapeutics by 1.2% in the first quarter. Goldman Sachs Group Inc. now owns 49,277 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 608 shares during the last quarter. Legal & General Group Plc increased its position in Akebia Therapeutics by 8.0% in the second quarter. Legal & General Group Plc now owns 9,672 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 714 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in Akebia Therapeutics by 1.0% in the second quarter. Wells Fargo & Company MN now owns 88,116 shares of the biopharmaceutical company’s stock worth $1,266,000 after buying an additional 880 shares during the last quarter. 62.82% of the stock is owned by institutional investors.

Shares of Akebia Therapeutics (NASDAQ AKBA) opened at $15.40 on Thursday. Akebia Therapeutics has a 52-week low of $7.78 and a 52-week high of $20.25.

Akebia Therapeutics (NASDAQ:AKBA) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.07. Akebia Therapeutics had a negative return on equity of 198.85% and a negative net margin of 137.80%. The company had revenue of $41.28 million for the quarter, compared to analyst estimates of $34.00 million. equities analysts expect that Akebia Therapeutics will post -2.25 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/07/akebia-therapeutics-inc-akba-receives-average-rating-of-buy-from-analysts.html.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.